Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update

References

• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439–448. doi:10.1056/NEJMoa1709866. PMID: 29385370; PMCID: PMC5996391.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Y. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. doi:10.1056/NEJMoa1707447. Epub 2017 Dec 10. PMID: 29226797; PMCID: PMC5882485.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Lia Palomba M, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. ISSN 0140-6736. doi:10.1016/S0140-6736(20)31366-0.
   PubMed Web of Science ®Google Scholar
• Munshi NC, LD A Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25;384(8):705–716. doi:10.1056/NEJMoa2024850. PMID: 33626253.
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed/refractory multiple myeloma: cARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20;41(6):1265–1274. doi:10.1200/JCO.22.00842. Epub 2022 Jun 4. PMID: 35658469; PMCID: PMC9937098.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. doi:10.1016/j.jclinepi.2009.06.005
   PubMed Web of Science ®Google Scholar
• Locke F L. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42. doi:10.1016/S1470-2045(18)30864-7
   PubMed Web of Science ®Google Scholar
• Chen Q, Staton A D, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700–1709. doi:10.1080/10428194.2017.1390230
   PubMed Web of Science ®Google Scholar
• Sung L, Buckstein R, Doyle J J, et al. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. Cancer. 2003;97(3):592–600. doi:10.1002/cncr.11098
   PubMed Web of Science ®Google Scholar
• Whittington M D, McQueen R Brett, Ollendorf D A, et al. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Netw Open. 2019;2(2):e190035. doi:10.1001/jamanetworkopen.2019.0035
   PubMed Web of Science ®Google Scholar
• Li N, Zheng B, Cai H, et al. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China. Support Care Cancer. 2022;30(7):6113–6121. doi:10.1007/s00520-022-07041-2
   PubMed Web of Science ®Google Scholar
• Locke F, Miklos D, Jacobson C. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386:640–654.
   PubMed Web of Science ®Google Scholar
• Kambhampati S. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140(19):2024–2036. doi:10.1182/blood.2022016747
   PubMed Web of Science ®Google Scholar
• Perales M, Kuruvilla J, Snider J Thornton, et al. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial. Transplant Cell Ther. 2022;28(11):750.e1–750.e6. doi:10.1016/j.jtct.2022.08.010
   PubMedGoogle Scholar
• Potnis K C, Di M, Isufi I, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023;7(5):801–810. doi:10.1182/bloodadvances.2022008097
   PubMed Web of Science ®Google Scholar
• Jacobson C A. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. doi:10.1016/S1470-2045(21)00591-X
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Lenalidomide for treated follicular lymphoma and marginal zone lymphoma; 2020 [cited2021 Sep 29]. Available from: https://www.nice.org.uk/guidance/ta627/evidence/committee-papers-pdf-8708812813
   Google Scholar
• Lin VW, Jiang Y, Chuang LH, et al. Health utilities for patients with relapsed or refractory large B-cell lymphoma: ad hoc analysis from an axicabtagene ciloleucel safety management study. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation; 2018 Mar 18–21; Lisbon, Portugal; 2018.
   Google Scholar
• Roth JA, Sullivan SD, Vincent W, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245. doi:10.1080/13696998.2018.1529674
   PubMed Web of Science ®Google Scholar
• Gye A, Goodall S, De Abreu Lourenco R. Cost-effectiveness Analysis of Tisagenlecleucel versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement. Pharmacoeconomics. 41(2): Epub ahead of print. PMID: 36266557:175–186. 2022 Oct 21. doi:10.1007/s40273-022-01188-w
   PubMed Web of Science ®Google Scholar
• Wakase S, Teshima T, Zhang J, et al. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. Transplant Cell Ther. 2021 Mar;27(3):241.e1. doi:10.1016/j.jtct.2020.12.023. Epub 2020 Dec 26. PMID: 33781519.
   Google Scholar
• Clinicaltrials.gov. Phase I/IIA study of CART19 cells for patients with chemotherapy resistant or refractory CD19+ leukemia and lymphoma (Pedi CART19); 2023 Jan 15.https://clinicaltrials.gov/ct2/show/NCT01626495
   Google Scholar
• Clinicaltrials.gov. Determine efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell ALL and high risk b-cell ALL at first relapse. Determine feasibility and safety of CTL019 therapy in pediatric patients with high risk B-cell ALL that relapsed < 6 months post all- HSCT. (ELIANA); 2023 Jan 15. https://clinicaltrials.gov/ct2/show/study/NCT02435849
   Google Scholar
• Clinicaltrials.gov. Study of efficacy and safety of CTL019 in pediatric ALL patients; 2023 Jan 15. https://clinicaltrials.gov/ct2/show/study/NCT02228096
   Google Scholar
• Kelly MJ, Pauker SG, Parsons SK. Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(5):790–797.
   PubMed Web of Science ®Google Scholar
• Maude SL, Pulsipher MA, MW B, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128(22):2801. doi:10.1182/blood.V128.22.2801.2801. Ash Orlando Florida.
   Web of Science ®Google Scholar
• Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. Journal of Clinical Oncology Conference. B2101J; virtual congress.
   Google Scholar
• Maude SL, Grupp SA, Mody R, et al. An updated analysis of tisagenlecleucel in pediatric/young adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) in a US multicenter clinical trial (ENSIGN). Hemasphere. 2018;2:4 ENSIGN.
   Google Scholar
• Essig S, von der Weid NX, Strippoli MPF, et al. Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemia. PLoS ONE. 2012;7(5):e38015. doi:10.1371/journal.pone.0038015
   PubMed Web of Science ®Google Scholar
• Walton M, Sharif S, Simmonds M, et al. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: an Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019 Oct;37(10):1209–1217. PMID: 30982165. doi:10.1007/s40273-019-00799-0.
   PubMed Web of Science ®Google Scholar
• Carey N, Leahy J, Trela-Larsen L, et al. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. Int J Technol Assess Health Care. 2022 Jul 11;38(1):e56. PMID: 35815435. doi:10.1017/S0266462322000356.
   PubMed Web of Science ®Google Scholar
• Whittington MD, Brett McQueen R, Ollendorf DA, et al. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Relapsed or Refractory Leukemia JAMA Pediatr. JAMA Pediatr. 2018;172(12):1161–1168. doi:10.1001/jamapediatrics.2018.2530
   PubMed Web of Science ®Google Scholar
• Ribera Santasusana JM, de Andrés Saldaña A, García-Muñoz NG, et al. Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain. Clinicoecon Outcomes Res. 2020 May 15:12:253–264. PMID: 32523362; PMCID: PMC7237114. doi:10.2147/CEOR.S241880
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory b-cell acute lymphoblastic leukemia. FDA Advisory Committee Briefing. Document(WA) DC: US Food and Drug Administration; 2017.
   Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917. doi:10.1200/JCO.2005.03.8554
   PubMed Web of Science ®Google Scholar
• Moradi-Lakeh M, Yaghoubi M, Seitz P, et al. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. Adv Ther. 2021 Jun;38(6):3427–3443. doi:10.1007/s12325-021-01767-x. Epub 2021 May 22. PMID: 34021886.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017 Dec 28;377(26):2545–2554. Epub 2017 Dec 10. PMID: 29226764; PMCID: PMC5788566. doi:10.1056/NEJMoa1708566.
   PubMed Web of Science ®Google Scholar
• Lin J K, Lerman B J, Barnes J I, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2018;36(32):3192–3202. doi:10.1200/JCO.2018.79.0642
   PubMed Web of Science ®Google Scholar
• Thielen FW, van Dongen-Leunis A, Arons AMM, et al. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. Eur J Haematol. 2020 Aug;105(2):203–215. doi:10.1111/ejh.13427. Epub 2020 May 4. PMID: 32289184; PMCID: PMC7497258.
   PubMed Web of Science ®Google Scholar
• Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in canada. JAMA Oncol. 2020 Mar 1;6(3):393–401. PMID: 31971547; PMCID: PMC6990832. doi:10.1001/jamaoncol.2019.5909.
   PubMed Web of Science ®Google Scholar
• Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program. 2014;2014(1):559–564.
   PubMed Web of Science ®Google Scholar
• Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL. press release. Basel Switzerland: Novartis: Jun 23, 2017
   Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia JNCI. J Natl Cancer Inst. 2019;111(7):1–8.
   PubMedGoogle Scholar
• Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043–6049. doi:10.1182/blood-2011-08-374710
   PubMed Web of Science ®Google Scholar
• Lin JK, Muffly LS, Spinner MA, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2018;37:2105–2119. doi:10.1200/JCO.18.02079
   Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med care. 2005;43(3):203–220.
   PubMed Web of Science ®Google Scholar
• Tengs TO, Wallace A. Wallace A: one thousand health-related quality-of-life estimates. Med care. 2000;38(6):583–637. http://www.ncbi.nlm.nih.gov/pubmed/10843310
   PubMed Web of Science ®Google Scholar
• Qi CZ, Bollu V, Yang H, et al. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-Cell lymphoma in the United States. Clin Ther. 2021 Aug;43(8):1300–1319. doi:10.1016/j.clinthera.2021.06.011. Epub 2021 Aug 8. PMID: 34380609.
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin’s disease. J Clin Oncol. 2006 Sep 1;24(25):4116–4122. PMID: 16943528. doi:10.1200/JCO.2006.07.0409.
   PubMed Web of Science ®Google Scholar
• Jun Wang X, Wang YH, Chau Tony Li S, et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective. J Med Econ. 2021;24(1):637–653.
   PubMed Web of Science ®Google Scholar
• Den Neste E V, Schmitz N, Mounier N. Mounier N et al Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51.
   PubMed Web of Science ®Google Scholar
• Registry CG. Study of efficacy and safety of CTL019 in adult DLBCL patients (JULIET), p. NCT02445248; 2015 [cited 2020 Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02445248.
   Google Scholar
• Piang Cher B, Yee Gan K, Ismail Abdul Aziz M, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective. J Med Econ. 2020;23(11):1321–1329.
   PubMed Web of Science ®Google Scholar
• Wang H, Manca A, Crouch S, et al. Health-state utility values in diffuse large B-cell lymphoma. Value Health. 2018;21:S74.
   Web of Science ®Google Scholar
• Choe JH, Abdel-Azim H, Padula WV, et al. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-Cell Lymphoma. JAMA Netw Open. 2022 Dec 1;5(12):e2245956. PMID: 36520440. doi:10.1001/jamanetworkopen.2022.45956.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J ClinOncol. 2014;32(10):1066–1073. doi:10.1200/JCO.2013.51.5866.
   PubMed Web of Science ®Google Scholar
• Norwegian Medicine Agency (NoMA). Single technology assessment: tisagenlecleucel (Kymriah) for the treatment of second or later relapsed/refractory diffuse large B cell lymphoma (DLBCL). Accessed Aug 18, 2021. https://legemiddelverket.no/Documents/Offentlig%20finansiering%20og%20pris/Metodevurderinger/K/Kymriah_DLBCL_2019.pd
   Google Scholar
• Bramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi:10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Cummings Joyner AK, Snider JT, Wade SW, et al. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: no Impact of Site of Care. Adv Ther. 2022 Aug;39(8):3560–3577. doi:10.1007/s12325-022-02188-0. Epub 2022 Jun 11. PMID: 35689726; PMCID: PMC9309131.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Chen JM, Chan K, et al. Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (Axi-Cel) and lisocabtagene maraleucel (Liso-Cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more prior lines of therapy. Presented at: 9th annual meeting of the Society of Hematologic Oncology (SOHO 2021); Sept 8–11; virtual. Abstract ABCL-289. 2021.
   Google Scholar
• Oluwole OO, Liu R, Diakite I, et al. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. J Med Econ. 2022;25(1):541–551.
   PubMed Web of Science ®Google Scholar
• Liu R, Oluwole OO, Diakite I, et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458–468.
   PubMed Web of Science ®Google Scholar
• Simons CL, Malone D, Wang M. Michael Wang, et al Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. J Med Econ. 2021;24(1):421–431.
   PubMed Web of Science ®Google Scholar
• Shah BD, Smith NJ, Feng C, et al. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Adv Ther. 2022 Aug;39(8):3678–3695. doi:10.1007/s12325-022-02201-6. Epub 2022 Jun 21. PMID: 35727476; PMCID: PMC9309154.
   PubMed Web of Science ®Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. doi:10.1016/S0140-6736(21)01222-8.
   PubMed Web of Science ®Google Scholar
• Shah B D, Ghobadi A, Oluwole, O O. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. doi:10.1016/S0140-6736(21)01222-8
   PubMed Web of Science ®Google Scholar
• Petersohn S, Salles G, Wang M, et al. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. J Med Econ. 2022;25(1):730–740. doi:10.1080/13696998.2022.2079317
   PubMed Web of Science ®Google Scholar
• Petrou P. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):529–536. doi:10.1080/14737167.2019.1651646. Epub 2019 Aug 19. PMID: 31422712.
   PubMed Web of Science ®Google Scholar
• Grigor EJM, Fergusson DA, Haggar F, et al. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. BMJ Open. 2017;7(12):e019321.
   Google Scholar
• Jogalekar MP, Rajendran RL, Khan F, et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022 Jul 22:13:925985. PMID: 35936003; PMCID: PMC9355792. doi:10.3389/fimmu.2022.925985
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808.
   PubMed Web of Science ®Google Scholar
• Panagiotis Petrou the quest for the in medio stat virtus price in the oncology sector. J Med Econ. 2018;21(10):1023–1025. doi:10.1080/13696998.2018.1499520
   PubMed Web of Science ®Google Scholar
• Petrou P. Budget impact analysis: can we afford the added value? J Med Econ. 2021 Jan;24(1):487–489. doi:10.1080/13696998.2021.1886108. PMID: 33544634.
   PubMed Web of Science ®Google Scholar
• Keating S, Gu T, Jun MP, et al. Health care resource utilization (HCRU) and total costs of care (TCOC) among patients (pts) with diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor (CAR) T-cell therapies in the United States: an analysis of four claims databases. J Clin Oncol. 2020;38:76.
   Web of Science ®Google Scholar
• Gajra A, Zalenski A, Sannareddy A, et al. Barriers To chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice. Pharmaceut Med. 2022 Jun;36(3):163–171. doi:10.1007/s40290-022-00428-w. Epub 2022 Jun 7. PMID: 35672571; PMCID: PMC9217916.
   PubMed Web of Science ®Google Scholar
• Patel U, Abernathy J, Savani BN, et al. CAR T cell therapy in solid tumors: a review of current clinical trials. eJHaem. 2022;3(Suppl. 1):24–31. doi:10.1002/jha2.356
   PubMedGoogle Scholar